NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise against tough lymphomas
Disease control CompletedThis study tested a combination of the drug lenalidomide with standard chemotherapy (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the safest dose and see how well the treatment controls the cancer. Results help doctors unders…
Matched conditions: NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, MOR00208 and lenalidomide, in 41 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination could shrink or control the cancer in patients who had not responded to prior treatments …
Matched conditions: NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC